Khiron Life Sciences Corp (OTCMKTS:KHRNF) Announces Receipt Of First Medical Cannabis Prescriptions For Project Twenty21 Participating Patients In The UK

Khiron Life Sciences Corp (OTCMKTS:KHRNF) has received the first medical cannabis prescriptions for Project Twenty21 patients in the UK. The clinics and doctors’ participating in the Project Twenty21 can now access Khiron branded EU GMP medical cannabis.

Project Twenty21 evaluates the effectiveness of medical cannabis

Project Twenty21 is initiated to investigate the tolerability and effectiveness of medical cannabis. After first announcing the participation in November 2019, Khiron prepares to supply for the Project Twenty21. Eminent personalities like Dr. Maria Fernanda Arboleda, Global Director (Medical Services) support the EU GMP medical cannabis supply. Khiron leverages its expertise gained from Colombia in making therapeutic recommendations and educational materials for the Project Twenty21, which expects to enroll 20,000 patients.

Professor David Nutt, who leads the project, said Khiron’s involvement in the Project Twenty21 significantly enhances formulary. The patients can get quick access to medical cannabis with the help of support extended by the team of Khiron.

Flexible to source medical cannabis from multiple nations

President of Khiron Europe, Tejinder Virk, said the receipt of the first prescriptions in the UK is a testament for its internationally diversified supply chain strategy and regulatory strengths. The company has the flexibility to get medical cannabis from several nations worldwide and ensure providing quality cannabis products at reasonable prices. Khiron has achieved milestones like virtual consultations implementation in the UK. It is also committed to mail order fulfillment and ensures healthy outcomes for the patients.

Signs a distribution deal with Medlive

Chris Naprawa, the president of Khiron, will present live at the fourth International cannabis virtual conference, which will be held at 11:40 AM ET on May 12, 2020. The company signed an exclusive accord with the distributor – Medlive, that serves three thousand hospitals and clinics in Brazil. It also entered a distribution agreement with Locatel for the distribution of medical cannabis in Colombia. Locatel serves more than two million patients in Colombia with healthcare products.

Other highlights

Khiron is the only company qualified to export THC products. It has received full authorization for the manufacture of low and high THC medical cannabis in Colombia on March 20, 2020. The company is operating health centers and cultivation facilities to cater to the needs of patients using the exemption granted by the Colombian government.

Leave a Reply

Your email address will not be published. Required fields are marked *

Acquisition Of ILANS Offers A Scalable And Secure Revenue Stream To Khiron Life Sciences Corp (OTCMKTS:KHRNF)

Pin It on Pinterest